Expert Interview
A Look at the new long-term for Gilead’s Livdelzi® (seladelpar) in Primary Biliary Cholangitis (PBC)
Ticker(s): GILDInstitution: University of Wisconsin
- Professor of Gastroenterology and Hepatology at the University of Wisconsin and Director of the Metabolic Liver Health Clinic
- Manages 80 patients with Primary Biliary Cholangitis
- Clinical Interest in PBC and currently serves as the Program Director of the Transplant Hepatology Fellowship program at UW
What are the most clinically meaningful takeaways from the new long-term and real-world Livdelzi (seladelpar) data in PBC, particularly around durability of biochemical response?
Added By: sara_adminHow do you interpret the ALP reductions seen in real-world use, including outcomes in patients switching from obeticholic acid. Does this align with what you would expect in your own practice?
Added By: sara_adminFrom a real-world implementation perspective, what factors will most influence long-term adoption of Livdelzi (e.g., patient selection, sequencing vs. OCA/fibrates, monitoring burden, tolerability, payer access)?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
